Regulome-guided drug repurposing identifies a losartan–tacrolimus combination for ulcerative colitis: from in silico ceRNA networks to exploratory in vivo outcomes

Introduction Ulcerative colitis (UC) is a chronic inflammatory condition influenced by genes, the immune system, and the environment. Many patients experience treatment failure, highlighting the need for novel strategies such as drug repurposing. In this study, we aim to evaluate the effects of losartan, an angiotensin receptor blocker, and tacrolimus, a calcineurin inhibitor, individually and in combination, for the exploratory study of their therapeutic effect in the treatment of UC. Method Computational analyses using miRDB, DisGeNET, RNAcentral, TargetScan, and Reactome were used to identify shared candidate genes, predicted ceRNA interactions (lncRNA/piRNA–miRNA–mRNA axes), and enriched pathways that are potentially relevant to UC. Selected molecular components identified within candidate ceRNA axes were subsequently assessed in a rat model of dextran sulfate sodium (DSS)-induced colitis treated for 3 weeks with losartan at a dose of 10 mg/kg/day, tacrolimus at 0.5 mg/kg/day, or a combination of both drugs. Clinical, hematological, qualitative histopathological, and molecular outcomes were examined. Molecular and biochemical endpoints were based on three independent animals per group. Results The computational analysis identified nine key shared genes, including STAT3, TNF-α, and IL-6, which are targets of miRNAs implicated in UC. In the animal model, combination therapy was associated with reductions in the measured abundance of selected inflammatory markers and partial restoration of miR-124-3p and miR-16 expression, compared to the individual drugs. Qualitative examination of representative colonic sections indicated improved tissue organization in treated groups (particularly in combination therapy) and in further restorations of hematological parameters. Conclusion The losartan–tacrolimus combination was associated with changes in selected inflammatory, molecular, hematological, and morphological outcomes in this exploratory DSS-induced colitis study. Together with the predicted ceRNA associations, these observed changes illustrate the potential of regulome-guided network analysis to prioritize candidate drug combinations for further investigation in complex inflammatory disorders.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.3389/fphar.2026.1918387
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Regulome-guided drug repurposing identifies a losartan–tacrolimus combination for ulcerative colitis: from in silico ceRNA networks to exploratory in vivo outcomes

Achraf El Allali, Ahmed Abdou El-Sherif, Ahmed Sayed Fouad, Mona M. Saber et al.
Frontiers in Pharmacology
Inflammatory Bowel Disease
article

Regulome-guided drug repurposing identifies a losartan–tacrolimus combination for ulcerative colitis: from in silico ceRNA networks to exploratory in vivo outcomes

Achraf El Allali, Ahmed Abdou El-Sherif, Ahmed Sayed Fouad, Mona M. Saber, Mohamed A. M. Atia, Rofayda Ihab
article en

Abstract

Introduction Ulcerative colitis (UC) is a chronic inflammatory condition influenced by genes, the immune system, and the environment. Many patients experience treatment failure, highlighting the need for novel strategies such as drug repurposing. In this study, we aim to evaluate the effects of losartan, an angiotensin receptor blocker, and tacrolimus, a calcineurin inhibitor, individually and in combination, for the exploratory study of their therapeutic effect in the treatment of UC. Method Computational analyses using miRDB, DisGeNET, RNAcentral, TargetScan, and Reactome were used to identify shared candidate genes, predicted ceRNA interactions (lncRNA/piRNA–miRNA–mRNA axes), and enriched pathways that are potentially relevant to UC. Selected molecular components identified within candidate ceRNA axes were subsequently assessed in a rat model of dextran sulfate sodium (DSS)-induced colitis treated for 3 weeks with losartan at a dose of 10 mg/kg/day, tacrolimus at 0.5 mg/kg/day, or a combination of both drugs. Clinical, hematological, qualitative histopathological, and molecular outcomes were examined. Molecular and biochemical endpoints were based on three independent animals per group. Results The computational analysis identified nine key shared genes, including STAT3, TNF-α, and IL-6, which are targets of miRNAs implicated in UC. In the animal model, combination therapy was associated with reductions in the measured abundance of selected inflammatory markers and partial restoration of miR-124-3p and miR-16 expression, compared to the individual drugs. Qualitative examination of representative colonic sections indicated improved tissue organization in treated groups (particularly in combination therapy) and in further restorations of hematological parameters. Conclusion The losartan–tacrolimus combination was associated with changes in selected inflammatory, molecular, hematological, and morphological outcomes in this exploratory DSS-induced colitis study. Together with the predicted ceRNA associations, these observed changes illustrate the potential of regulome-guided network analysis to prioritize candidate drug combinations for further investigation in complex inflammatory disorders.

Frontiers in PharmacologyVol. 17
Cairo University (EG), Egypt-Japan University of Science and Technology (EG), Université Mohammed VI Polytechnique (MA)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon